Hirnstruktur und Hirnfunktion: Die Rolle der Omega-3-Fettsäuren

Zusammenfassung

Eine unzureichende Versorgung mit Eicosapentaen- (EPA) und Docosahexaensäure (DHA) prädisponiert während der gesamten Lebensspanne zu suboptimaler Hirnstruktur und -funktion. Erhöht man die Zufuhr dieser Omega-3-Fettsäuren gezielt auf Basis des HS-Omega-3-Index, können kognitive Fähigkeiten erhalten bzw. verbessert werden.

Schlüsselwörter

Omega-3-Fettsäuren - Docosahexaensäure - Eicosapentaensäure - HS-Omega-3-Index - Gehirnstruktur - Hirnleistung - ADHS - Depression

• Literatur

• 1 von Schacky C. The Omega-3 Index as a Risk Factor for Cardiovascular Diseases. Prostaglandins Other Lipid Mediat 2011; 96: 94-98
• 2 Koletzko B, Cetin I, Brenna JT et al.. Dietary fat intakes for pregnant and lactating women. Br J Nutr 2007; 98: 873-877
• 3 Mulder KA, King DJ, Innis SM. Omega-3 Fatty Acid Deficiency in Infants before Birth Identified Using a Randomized Trial of Maternal DHA Supplementation in Pregnancy. PLoS One 2014; 9 (1) e83764
• 4 Kuratko CN, Barrett EC, Nelson EB, Salem N. The Relationship of Docosahexaenoic Acid (DHA) with Learning and Behavior in Healthy Children: A Review. Nutrients 2013; 5: 2777-2810
• 5 Montgomery P, Burton JR, Sewell RP et al. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and behavior: a cross-sectional analysis from the DOLAB study. PLoS One 2013; 8 (6) e66697
• 6 Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2011; 50: 991-1000
• 7 Milte CM, Parletta N, Buckley JD et al. Increased Erythrocyte Eicosapentaenoic Acid and Docosahexaenoic Acid Are Associated With Improved Attention and Behavior in Children With ADHD in a Randomized Controlled Three-Way Crossover Trial. J Atten Disord 2013; Nov 8. [Epub ahead of print]
• 8 Pottala JV, Churchill SW, Talley JA et al. Red Blood Cell Fatty Acids are Associated with Depression in a Case-Control Study of Adolescents. Prostaglandins Leukot Essent Fatty Acids 2012; 86: 161-165
• 9 Baghai TC, Varallo-Bedarida G, Born C et al. Major depression is associated with cardiovascular risk factors and low Omega-3 Index. J Clin Psychiat 2011; 72: 1242-1247
• 10 Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 2011; 72: 1577-1584
• 11 Johnston DT, Deuster PA, Harris WS et al. Red blood cell omega-3 fatty acid levels and neurocognitive performance in deployed U.S. Servicemembers. Nutr Neurosci 2013; 16: 30-38
• 12 Stonehouse W, Conlon CA, Podd J et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am J Clin Nutr 2013; 97: 1134-1143
• 13 Tan ZS, Harris WS, Beiser AS et al. Red Blood Cell Omega-3 Fatty Acid Levels and Markers of Accelerated Brain Aging. Neurology 2012; 78: 658-664
• 14 Pottala JV, Yaffe K, Robinson J et al. Higher RBC EPA+DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study. Neurology 2014; 82: 435-442
• 15 Witte AV, Kerti L, Hermannstädter HM et al. Long-Chain Omega-3 Fatty Acids Improve Brain Function and Structure in Older Adults. Cereb Cortex 2013; Jun 24. [Epub ahead of print]
• 16 Mazereeuw G, Lanctôt KL, Chau SA et al. Effects of ω-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging 2012; 33: 1482.e17-29
• 17 Quinn JF, Raman R, Thomas RG et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010; 304: 1903-1911
• 18 Shi J, Leporé N, Gutman BA et al. Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimerʼs disease neuroimaging initiative study. Hum Brain Mapp 2014; Jan 22 [Epub ahead of print]
• 19 Cunnane SC, Chouinard-Watkins R, Castellano CA, Barberger-Gateau P. Docosahexaenoic acid homeostasis, brain aging and Alzheimerʼs disease: Can we reconcile the evidence?. Prostaglandins Leukot Essent Fatty Acids 2013; 88: 61-70
• 20 Lopez AD, Murray CC. The global burden of disease, 1990–2020. Nat Med 1998; 4: 1241-1243
• 21 Bundesinstitut für Risikobewertung. Gesundheitliche Bewertung von Nahrungsergänzungsmitteln. Im Internet: http://www.bfr.bund.de/de/gesundheitliche_bewertung_von_nahrungsergaenzungsmitteln-945.html Stand: Januar 2014